Presse medicale (Paris, France : 1983) · 2003
[Which antithrombotic treatment should be used in the treatment of an elderly patient with chronic atrial fibrillation?].
Сравнительное исследованиеАннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahé I, Grenard A S, Caulin C, Bergmann J F
Аннотация
UNLABELLED: FREQUENCY AND CONSEQUENCES: The incidence of atrial fibrillation (AF) increases regularly with age and affects nearly 10% of persons aged over 80. The risk of thromboembolism (notably stroke) associated is enhanced the older the patient and the more cardiovascular risk factors she/he exhibits. ADVANTAGES AND RISKS OF ANTICOAGULANTS: Treatment with anticoagulants is the only treatment that has demonstrated its efficacy in reducing the risks of thromboembolism, however there is a risk of haemorrhage.
IN PRACTICE: A patient with AF exhibits both a risk of thromboembolism and a risk of haemorrhage. When confronted with such patients, the practitioner must choose an antithrombotic (anticoagulant or anti-arrhythmic agent) after careful objective and individual assessment of all the risks present in a given patient.
IN PRACTICE: A patient with AF exhibits both a risk of thromboembolism and a risk of haemorrhage. When confronted with such patients, the practitioner must choose an antithrombotic (anticoagulant or anti-arrhythmic agent) after careful objective and individual assessment of all the risks present in a given patient.
Предметные рубрики MeSH
Age FactorsAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAspirinAtrial FibrillationChronic DiseaseClinical Trials as TopicEchocardiographyFemaleFibrinolytic AgentsHemorrhageHumansMaleMiddle AgedMulticenter Studies as TopicPlatelet Aggregation InhibitorsPrimary PreventionRecurrenceRisk AssessmentRisk FactorsStrokeThromboembolismTime Factors